R. Spiller
Guidelines for the management of Irritable Bowel Syndrome
Spiller, R.; Aziz, Q.; Creed, F.; Emmanuel, A.; Houghton, L.; Hungin, A.P.; Jones, R.; Kumar, D.; Rubin, G.; Trudgill, N.; Whorwell, P.
Authors
Q. Aziz
F. Creed
A. Emmanuel
L. Houghton
A.P. Hungin
R. Jones
D. Kumar
G. Rubin
N. Trudgill
P. Whorwell
Abstract
Background: IBS affects 5–11% of the population of most countries. Prevalence peaks in the third and fourth decades, with a female predominance. Aim: To provide a guide for the assessment and management of adult patients with irritable bowel syndrome. Methods: Members of the Clinical Services Committee of The British Society of Gastroenterology were allocated particular areas to produce review documents. Literature searching included systematic searches using electronic databases such as Pubmed, EMBASE, MEDLINE, Web of Science, and Cochrane databases and extensive personal reference databases. Results: Patients can usefully be classified by predominant bowel habit. Few investigations are needed except when diarrhoea is a prominent feature. Alarm features may warrant further investigation. Adverse psychological features and somatisation are often present. Ascertaining the patients’ concerns and explaining symptoms in simple terms improves outcome. IBS is a heterogeneous condition with a range of treatments, each of which benefits a small proportion of patients. Treatment of associated anxiety and depression often improves bowel and other symptoms. Randomised placebo controlled trials show benefit as follows: cognitive behavioural therapy and psychodynamic interpersonal therapy improve coping; hypnotherapy benefits global symptoms in otherwise refractory patients; antispasmodics and tricyclic antidepressants improve pain; ispaghula improves pain and bowel habit; 5-HT3 antagonists improve global symptoms, diarrhoea, and pain but may rarely cause unexplained colitis; 5-HT4 agonists improve global symptoms, constipation, and bloating; selective serotonin reuptake inhibitors improve global symptoms. Conclusions: Better ways of identifying which patients will respond to specific treatments are urgently needed.
Citation
Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L., Hungin, A., …Whorwell, P. (2007). Guidelines for the management of Irritable Bowel Syndrome. Gut, 56(12), 1770-1798. https://doi.org/10.1136/gut.2007
Journal Article Type | Article |
---|---|
Publication Date | May 1, 2007 |
Deposit Date | Apr 4, 2012 |
Journal | Gut |
Print ISSN | 0017-5749 |
Electronic ISSN | 1468-3288 |
Publisher | BMJ Publishing Group |
Peer Reviewed | Peer Reviewed |
Volume | 56 |
Issue | 12 |
Pages | 1770-1798 |
DOI | https://doi.org/10.1136/gut.2007 |
You might also like
Transition from childhood to adulthood in coeliac disease: the Prague consensus report
(2016)
Journal Article
What calprotectin cut-offs should apply for IBD in general practice?
(2016)
Journal Article
Faecal biomarker patterns in patients with symptoms of irritable bowel syndrome
(2016)
Journal Article
Downloadable Citations
About Durham Research Online (DRO)
Administrator e-mail: dro.admin@durham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search